Could Stem Cells Eventually End the Transplant Organ Shortage? – HowStuffWorks
|
Could Stem Cells Eventually End the Transplant Organ Shortage?
HowStuffWorks If a patient’s own stem cells could be manipulated to grow a personalized replacement for an ailing heart, liver, kidneys or another organ, that would help solve the supply/match problem. Additionally, a transplant organ wouldn’t face the risk of … |
Market Realist |
How Juno Therapeutics’ Cellular Immunotherapy Portfolio Could Help Celgene
Market Realist (To know more on Novartis’ Kymriah, please refer to Market Realist’s “How Is Novartis’s Kymriah Positioned for 2018?“) In October 2017, the FDA approved Gilead Sciences’ Yescarta for the treatment of certain types of non-Hodgkin lymphoma. The … Here’s Why Fate Therapeutics Rose as Much as 18% TodayMadison.com Juno Therapeutics (JUNO) Lowered to Sell at Zacks Investment ResearchThe Ledger Gazette Celgene’s $9B Buyout of Juno to Boost Company’s Immuno-Oncology PortfolioImmuno-Oncology News Brinkwire (press release) all 89 news articles » |
USC News |
Stem cells used to build bone and fight cancer | USC News
USC News histology of neuroblastoma cells Abigail Zamora will study the cells that cause neuroblastoma, an aggressive cancer that often affects children. (Photo/ Ed Uthman). This year’s Broad Clinical Research Fellows will apply stem cell-based approaches to … |
|
Targeting bladder cancer’s Achilles heel: Stem cells
Science Daily Recent research suggests that this resistance is caused by a small pool of cancer stem cells (CSCs) within these tumors that isn’t killed with chemotherapies, leading tumors to regrow and spread even after initial treatment success. Although … |